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Recently, two powerful prognostic models were described in myeloma. The Intergroupe Francophone du Mye'lome (IFM) model uses genetic factors t(4;14) and/or 17p13 deletion by fluorescent in situ hybridization combined with b-2 microglobulin. The high-risk group in this model, defined by the presence of either t(4;14) or 17p13 depletion and b-2 microglobulin greater than 4 mg l À1 , could dissect the survival of patients in each International Staging Study stage. 1 As the International Staging Study did not fully consider genetic factors, this study in a large cohort of patients definitively validates the importance of genetic factors in multiple myeloma prognosis. The other model from the University of Arkansas School of Medical Sciences (UAMS) is based on the expression of 17 genes (17-gene model). The high-risk index based on this model is an extremely powerful prognostic factor with a hazard ratio in excess of 4.
2 It can also further dissect patients with t(4;14) into two groups with significantly different survival. In this study, first we wanted to validate the prognostic significance of the 17-gene high-risk index in other independent (non-UAMS) data sets, and second examine the relationship between high-risk genetic features and the 17-gene high-risk molecular signature.
For the first objective, we analyzed a Mayo Clinic gene expression profile data set comprising 71 newly diagnosed multiple myeloma patients treated with high-dose melphalan and stem cell transplant (previously published and available in Gene Expression Omnibus, accession number GSE 6477), 3 and for the second objective we analyzed the UAMS data set of 351 newly diagnosed patients treated with total therapy II from the UAMS (Gene Expression Omnibus accession GSE 2658). 4 Both data sets were performed on Affymetrix platform. In the Mayo data set, gene expression profile was performed on malignant plasma cells enriched by positive immunomagnetic selection using CD138 (AutoMACS; Miltenyi-Biotec, Auburn, CA, USA). Bone marrow samples were obtained after informed consent according to the Declaration of Helsinki Principles. The study was approved by the Mayo Clinic Institutional Review Board. CD138 selection was also used to enrich for malignant plasma cells in the UAMS data set. Gene expression intensity values were generated using the Affymetrix MAS 5.0 software, median-centered and analyzed using GeneSpring GX 7.3.1 (Agilent Technologies, Palo Alto, CA, USA). The 17-gene high-risk score is calculated based on published methods.
2 A gene expression profile based proliferation index (PI) was calculated as the median expression of the following genes: CCNB1, MKI67, L5, KIAA0186, CKS1B, TOP2A, UBE2C, ZWINT, 16E1BP, TRIP5, CCNA, p55CDC.
5 Spiked expression of FGFR3 or WHSC1 defines cases with t(4;14). 5 Low TP53 expression was used as a surrogate for 17p13 deletion, as a recent study showed that there is a close association between the cases with lowest TP53 expression and 17p13 deletion. 6 The associations between prognostic factors were assessed using Fisher's exact test. The distribution for overall survival was estimated using the method of Kaplan and Meier. The log-rank test was used to test for differences in survival between groups. Overall survival was calculated from diagnosis to death. A P-value of o0.05 was considered significant.
To validate the 17-gene high-risk signature, we analyzed the Mayo Clinic data set. Nine of 71 (13%) Mayo patients have a high-risk 17-gene index. These high-risk patients have significantly shorter survival (Figure 1) .
A number of genes used to define the high-risk 17-gene index are proliferation-related genes. To assess the relationship between the high-risk index, proliferation and high-risk genetic factor such as t(4;14), we utilized the UAMS data set, which is large enough for meaningful subset analysis. There is a close relationship between a high-risk 17-gene index and high PI (42), as only 6 out of 38 multiple myeloma with high PI did not also have a high-risk index. On the other hand, the overlap with t(4;14) is less, with less than half of t(4;14) patients having a high-risk index ( Figure 2 ). As expected, high-risk 17-gene index is highly associated with a high PI (Fisher's exact Po0.0001) whereas t(4;14) is not significantly associated with a high PI (Fisher's exact P ¼ 0.06).
Next, we wanted to see if genetic factors still have prognostic importance in the setting of the 17-gene model. This analysis was again performed in the UAMS data set. We found that t(4;14) or low TP53 expression was associated with poorer survival when applied to all patients (data not shown). However, only the t(4;14) and not low p53 expression was able to further dissect the survival of high-risk patients defined by the 17-gene model ( Figure 3 ).
Our analysis validates that the high-risk molecular signature is a powerful prognostic factor when applied to an independent data set, but also suggests that high-risk genetics such as t (4;14) is still relevant even in the presence of this high-risk molecular signature. Although recent studies have shown that t(4;14) patients can be further dissected, 1,2,7 our analysis is the first to show that poor-risk patients defined by the high-risk molecular signature can also be further dissected. It is clear that the heterogeneity within myeloma is complex. Understanding this heterogeneity in the context of any new prognostic marker will be important for clinical decision and development of novel therapeutic strategies. The advantage of genetics factors is that they reflect underlying biology and provide a means of specifically targeting the deregulated genes and pathways, for example FGFR3 inhibitors in t(4;14) multiple myeloma. 8, 9 In contrast, the biology driving the high-risk molecular signature is still unclear although part of its effect is likely to be mediated through proliferation.
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